These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21548720)

  • 1. Exenatide once weekly in type 2 diabetes mellitus.
    Bischoff LA; Jabbour SA; Miller JL
    Expert Opin Pharmacother; 2011 Jun; 12(8):1297-1303. PubMed ID: 21548720
    [No Abstract]   [Full Text] [Related]  

  • 2. Exenatide for once-weekly administration.
    Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release exenatide (Bydureon) for type 2 diabetes.
    Med Lett Drugs Ther; 2012 Mar; 54(1386):21-3. PubMed ID: 22421818
    [No Abstract]   [Full Text] [Related]  

  • 4. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.
    Murphy CE
    Ann Pharmacother; 2012 Jun; 46(6):812-21. PubMed ID: 22669803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
    Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
    Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.
    Anderson ZL; Clements JN
    JAAPA; 2014 Jun; 27(6):44-6. PubMed ID: 24853156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
    Doggrell SA
    Expert Opin Pharmacother; 2011 Sep; 12(13):2055-67. PubMed ID: 21534885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly glucagon-like peptide 1 receptor agonists.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
    Ahrén B
    Lakartidningen; 2007 Dec; 104(49-50):3763-4. PubMed ID: 18214322
    [No Abstract]   [Full Text] [Related]  

  • 10. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
    J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the incretin system in type 2 diabetes mellitus.
    Potenza M; Rayfield EJ
    Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longacting exenatide in diabetes: DURATION-3.
    Misra A; Joshi S
    Lancet; 2010 Jun; 375(9733):2198-9. PubMed ID: 20609957
    [No Abstract]   [Full Text] [Related]  

  • 13. Hormone copycats.
    Gebel E
    Diabetes Forecast; 2012 Jun; 65(6):36, 38-9. PubMed ID: 22737769
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL; Lloyd A; Best JH; DeYoung MB; Samyshkin Y; Gaebler JA
    J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glucagon-like peptide-1 receptor agonists].
    Kurose T; Seino Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():689-92. PubMed ID: 22768599
    [No Abstract]   [Full Text] [Related]  

  • 16. Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.
    Brunton S; Davidson JA
    Clin Ther; 2016 Mar; 38(3):582-94. PubMed ID: 26926319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and strategies for moving patients to injectable medications.
    Siminerio L
    Diabetes Educ; 2006; 32 Suppl 2():82S-90S. PubMed ID: 16554432
    [No Abstract]   [Full Text] [Related]  

  • 19. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans.
    Xiao C; Bandsma RH; Dash S; Szeto L; Lewis GF
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1513-9. PubMed ID: 22492091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.